BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
BiomX Inc. (NYSE American: PHGE), a clinical-stage company focused on phage therapies, has disclosed that its independent registered public accounting firm included a going concern qualification in their audit opinion for the fiscal year ended December 31, 2024. This disclosure, which was previously included in the Company's annual report on Form 10-K filed on March 25, 2025, is being announced separately to comply with NYSE American Company Guide Sections 401(h) and 610(b). The company emphasizes that this announcement does not represent any changes or amendments to their 2024 audited financial statements or annual report.
BiomX Inc. (NYSE American: PHGE), una società in fase clinica focalizzata sulle terapie a base di fagi, ha comunicato che la sua società di revisione contabile indipendente ha incluso una qualificazione di continuità aziendale nella loro opinione di revisione per l'anno fiscale conclusosi il 31 dicembre 2024. Questa comunicazione, precedentemente inclusa nel rapporto annuale della Società sul modulo 10-K depositato il 25 marzo 2025, viene annunciata separatamente per conformarsi alle Sezioni 401(h) e 610(b) del NYSE American Company Guide. L'azienda sottolinea che questo annuncio non rappresenta alcuna modifica o emendamento ai loro bilanci finanziari auditati del 2024 o al rapporto annuale.
BiomX Inc. (NYSE American: PHGE), una empresa en etapa clínica centrada en terapias con fagos, ha revelado que su firma de contabilidad pública registrada independiente incluyó una calificación de continuidad en su opinión de auditoría para el año fiscal que terminó el 31 de diciembre de 2024. Esta divulgación, que se incluyó previamente en el informe anual de la empresa en el formulario 10-K presentado el 25 de marzo de 2025, se anuncia por separado para cumplir con las Secciones 401(h) y 610(b) de la Guía para Empresas de NYSE American. La empresa enfatiza que este anuncio no representa ningún cambio o enmienda a sus estados financieros auditados de 2024 o al informe anual.
BiomX Inc. (NYSE American: PHGE)는 파지 치료에 중점을 둔 임상 단계 회사로, 독립 등록 공인 회계 법인이 2024년 12월 31일 종료된 회계 연도에 대한 감사 의견서에 계속 기업에 대한 자격을 포함했다고 밝혔습니다. 이 공시는 2025년 3월 25일에 제출된 10-K 양식의 회사 연례 보고서에 이전에 포함되었으며, NYSE American Company Guide의 401(h) 및 610(b) 섹션을 준수하기 위해 별도로 발표됩니다. 회사는 이 발표가 2024년 감사 재무제표나 연례 보고서에 대한 변경이나 수정 사항을 나타내지 않는다고 강조합니다.
BiomX Inc. (NYSE American: PHGE), une entreprise en phase clinique axée sur les thérapies par phages, a annoncé que son cabinet d'expertise comptable public indépendant avait inclus une qualification de continuité dans son opinion d'audit pour l'exercice clos le 31 décembre 2024. Cette divulgation, qui avait été précédemment incluse dans le rapport annuel de l'entreprise sur le formulaire 10-K déposé le 25 mars 2025, est annoncée séparément pour se conformer aux Sections 401(h) et 610(b) du NYSE American Company Guide. L'entreprise souligne que cette annonce ne représente aucun changement ou amendement à ses états financiers audités de 2024 ou à son rapport annuel.
BiomX Inc. (NYSE American: PHGE), ein klinisches Unternehmen, das sich auf Phagentherapien konzentriert, hat bekannt gegeben, dass die unabhängige registrierte Wirtschaftsprüfungsgesellschaft eine Fortführungsprognose in ihr Prüfungsurteil für das am 31. Dezember 2024 endende Geschäftsjahr aufgenommen hat. Diese Offenlegung, die zuvor im Jahresbericht des Unternehmens auf dem Formular 10-K eingereicht am 25. März 2025 enthalten war, wird separat bekannt gegeben, um den Abschnitten 401(h) und 610(b) des NYSE American Company Guide zu entsprechen. Das Unternehmen betont, dass diese Ankündigung keine Änderungen oder Änderungen an ihren geprüften Finanzberichten für 2024 oder dem Jahresbericht darstellt.
- None.
- Received going concern qualification from auditors, indicating substantial doubt about company's ability to continue operations
- Potential financial stability issues suggested by the going concern opinion
NESS ZIONA, Israel, April 01, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced that, as previously disclosed in its annual report on Form 10-K for the fiscal year ended December 31, 2024, which was filed with the Securities and Exchange Commission on March 25, 2025, the audit opinion contained a going concern qualification from the Company's independent registered public accounting firm. This announcement is being made solely to comply with the NYSE American Company Guide Sections 401(h) and 610(b), which require separate disclosure of receipt of an audit opinion that contains a going concern qualification. This announcement does not represent any change or amendment to the Company's 2024 audited financial statements or to its 2024 annual report on Form 10-K.
About BiomX
BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visit https://www.biomx.com/, the content of which does not form a part of this press release.
Contacts:
BiomX Inc.
Ben Cohen
Head Corporate Communications
benc@biomx.com
FAQ
What does the going concern qualification mean for BiomX (PHGE) investors?
When did BiomX (PHGE) receive the going concern audit opinion?
Why did BiomX (PHGE) make this separate NYSE announcement?
Does this announcement change BiomX's (PHGE) 2024 financial statements?
